DeepMed Research

CFI-400945

Generic Name: CFI-400945

Clinical Trials

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

Phase 1

Active, not recruiting

Conditions: AML
MDS
Myelodysplastic Syndromes
CMML
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia

Interventions: Drug: CFI-400945
Drug: Azacitidine

First Posted Date: 2021-01-29

Last Posted Date: 2025-05-18

Lead Sponsor: Treadwell Therapeutics, Inc

Target Recruit Count: 72

Registration Number: NCT04730258

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Norton Cancer Institute - Saint Matthews, Louisville, Kentucky, United States
🇺🇸
New York Presbyterian Weill Cornell Medical Center, New York, New York, United States

and more 6 locations

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: CFI-400945
Drug: Durvalumab

First Posted Date: 2019-11-25

Last Posted Date: 2025-03-10

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 15

Registration Number: NCT04176848

Locations: 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

and more 2 locations

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: CFI-400945

First Posted Date: 2018-08-10

Last Posted Date: 2025-02-17

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 51

Registration Number: NCT03624543

Locations: 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada

and more 3 locations

Prostate Cancer Biomarker Enrichment and Treatment Selection

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Savolitinib
Drug: Darolutamide
Drug: Durvalumab and Tremelimumab
Drug: CFI-400945
Drug: Adavosertib
Drug: Ipatasertib
Drug: Carboplatin

First Posted Date: 2017-12-28

Last Posted Date: 2025-03-17

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 200

Registration Number: NCT03385655

Locations: 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

and more 8 locations

Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Relapsed Cancer
Myelodysplastic Syndromes
Refractory Cancer

Interventions: Drug: CFI-400945 Fumarate

First Posted Date: 2017-06-14

Last Posted Date: 2024-08-22

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 13

Registration Number: NCT03187288

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦
Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada

A Study of CFI-400945 Fumarate in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: CFI-400945

First Posted Date: 2013-10-01

Last Posted Date: 2024-01-17

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 46

Registration Number: NCT01954316

Locations: 🇺🇸
UCLA Medical Center, Santa Monica, California, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy